(0.34%) 5 117.14 points
(0.33%) 38 367 points
(0.38%) 15 989 points
(-0.95%) $83.05
(5.56%) $2.03
(0.35%) $2 355.30
(0.44%) $27.66
(4.06%) $959.55
(-0.25%) $0.932
(-0.41%) $10.98
(-0.56%) $0.796
(1.69%) $93.43
@ CNY1.720
発行日: 13 2月 2024 @ 23:31
リターン: 4.66%
前回のシグナル: 2月 10 - 00:06
前回のシグナル:
リターン: -6.01 %
Live Chart Being Loaded With Signals
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial...
Stats | |
---|---|
本日の出来高 | 185 821 |
平均出来高 | 360 150 |
時価総額 | 149.39M |
EPS | CNY0 ( 2024-03-29 ) |
Last Dividend | CNY0 ( N/A ) |
Next Dividend | CNY0 ( N/A ) |
P/E | -0.480 |
ATR14 | CNY0.00600 (0.33%) |
I-Mab 相関
10 最も負の相関 | |
---|---|
DWSH | -0.806 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
I-Mab 財務諸表
Annual | 2023 |
収益: | CNY27.64M |
総利益: | CNY27.64M (100.00 %) |
EPS: | CNY-16.53 |
FY | 2023 |
収益: | CNY27.64M |
総利益: | CNY27.64M (100.00 %) |
EPS: | CNY-16.53 |
FY | 2022 |
収益: | CNY-221.56M |
総利益: | CNY-248.80M (112.29 %) |
EPS: | CNY-31.75 |
FY | 2021 |
収益: | CNY88.03M |
総利益: | CNY41.59M (47.25 %) |
EPS: | CNY-29.19 |
Financial Reports:
No articles found.
I-Mab
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。